Skip to Content Facebook Feature Image

cpThrive: A first-of-its-kind digital guide to help identify evidence-based cerebral palsy treatments

Business

cpThrive: A first-of-its-kind digital guide to help identify evidence-based cerebral palsy treatments
Business

Business

cpThrive: A first-of-its-kind digital guide to help identify evidence-based cerebral palsy treatments

2026-01-20 13:46 Last Updated At:14:05

SYDNEY, Jan. 20, 2026 /PRNewswire/ -- Cerebral Palsy Alliance, The University of Sydney, and CSIRO, Australia's national science agency, have commissioned Miroma Project Factory to deliver a groundbreaking mobile app that helps people with cerebral palsy (CP), their carers, and clinicians understand and navigate evidence-based treatments with confidence.

Developed as part of the national TRANSMIT project (Translation Strategy Improving Function), cpThrive transforms decades of research into an easy-to-use "traffic light" guide, helping people with lived experience of CP to quickly identify therapies tailored to individual priorities and needs. The app could not have been developed without the support of our incredible research partners with lived experience, Children's Health Queensland, and The Sydney Children's Hospital Network.

cpThrive is an accessible, personalised, user-friendly tool designed through a thorough co-design process with people living with CP, clinicians, researchers, and policy experts. The app aims to improve functional outcomes and inform access to proven therapies across Australia.

The cpThrive app contains over 130 medical, allied health and other treatments. Short videos, collected from across Australia and internationally, demonstrate real-life therapy examples. The app is based on the globally recognised work of Professor Iona Novak, Dr Michelle Jackman, Dr Dana Bradford, Professor Nadia Badawi, Dr Cathy Morgan, Professor Leanne Sakzewski, Professor Roslyn Boyd, Professor Michael Fahey, and Dr Maria Mc Namara, in collaboration with the research team at Cerebral Palsy Alliance and other partners.

"This app is an important step in bridging the gap between research and real-world care. Evidence doesn't help if it stays in academic papers. cpThrive ensures that what we know works is actually used by those who need it most," said Professor Iona Novak.

The app aims to close the gap between the therapies we know that work and what gets implemented. Currently, only 55% of people receive effective therapy, while 43% receive treatments that may be ineffective or even harmful. cpThrive sets out to change that.

Miroma Project Factory securely designed and developed cpThrive as a Flutter-based mobile app with a solid back end and a user-centred experience. The app forms part of a national five-year research program funded by the National Health and Medical Research Council (NHMRC), and supported by the National Disability Insurance Agency, and leading CP researchers from The University of Sydney, CSIRO and The University of Queensland.

cpThrive will launch in Australia shortly and will continue to evolve based on user feedback and ongoing research outcomes.

The app will also help researchers understand how access to reliable, evidence-based information will benefit families.

Key features of the cpThrive app

  • Tailored app experiences for people with CP, and their carers.
  • Save favourite therapies, get real-time feedback, and view treatment options based on personal priorities.
  • Built-in accessibility features such as large text and screen reader compatibility.
  • Simple participation process for the national research study.
  • Easy updating and reporting tools for researchers.
  • Secure data storage that meets national research and privacy standards.

Call for families to sign up!

Six hundred families are needed to download the app, register their details, and start using it, providing feedback through a short survey every three months. Feedback from people with lived experience will be used to capture positive and negative feedback for designers and researchers to review and update the app.

By bringing decades of research into a practical digital tool, the app bridges the gap between science and everyday life, helping families, carers, and clinicians make confident, informed decisions that improve outcomes and quality of life.

About Miroma Project Factory (MPF)

MPF is a multi-award-winning digital strategy and product studio that delivers innovative digital solutions across web, platforms, and systems. Specialising in purposeful technology, MPF works at the intersection of strategy, design, and engineering to create impactful digital products for organisations ready to lead. With deep expertise in healthcare, MPF helps clients scale responsibly, communicate clearly, and connect meaningfully with their audiences. For more information, visit www.theprojectfactory.com.

For media enquiries, interviews or partnership opportunities, please contact:
Miroma Project Factory
info@theprojectfactory.com

Media enquiries Cerebral Palsy Alliance – Rebecca McCartney, rebecca.mccartney@cerebralpalsy.org.au 

Media enquiries CSIRO – Naomi Stekelenburg, Naomi.stekelenburg@csiro.au

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

cpThrive: A first-of-its-kind digital guide to help identify evidence-based cerebral palsy treatments

cpThrive: A first-of-its-kind digital guide to help identify evidence-based cerebral palsy treatments

DEERFIELD, Ill., Jan. 21, 2026 /PRNewswire/ -- Baxter Healthcare is pleased to share the growing success of the room temperature storage configuration of Hemopatch Sealing Hemostat, launched earlier, this Summer, across Australia and New Zealand. Since its introduction, the product has been met with enthusiastic adoption by surgical teams who value convenience, versatility, and clinical performance.

Hemopatch Sealing Hemostat is a ready-to-use, absorbable collagen pad designed for tissue sealing and hemostasis.1 The new room temperature format eliminates the need for refrigeration, streamlining preparation and storage in operating rooms.1 Surgeons across the region are finding significant value in the product's ability to manage mild to moderate bleeding scenarios with confidence.

"Hemopatch Sealing Hemostat is an excellent product that is quite versatile across many urological operations. The ability to handle venous bleeding across wide surfaces is great for patients and has allowed me to confidently use Hemopatch Sealing Hemostat," said Urological Surgeon, A/Prof Matthew Roberts from Queensland, Australia.

Baxter is proud to deliver meaningful value to clinicians through innovations like Hemopatch Sealing Hemostat, and empowering surgical teams in achieving their desired patient outcomes. The product's strong reception underscores our commitment to providing solutions that help save and sustain lives.

With a shelf life of up to 36 months and compatibility with both open and minimally invasive procedures, Hemopatch Sealing Hemostat continues to be a trusted tool in operating rooms across Australia and New Zealand.1

For more information on Hemopatch Sealing Hemostat,  
Visit: https://advancedsurgery.baxter.eu/hemopatch 

Reference:

Manufacturer:

Baxter Healthcare SA
Thurgauerstrasse 130 Glattbrugg,
ZÜRICH, 8152 Switzerland

Class of Device: III
CE0123

This content is intended solely for healthcare professionals and should not be interpreted as medical advice. Please consult with a qualified healthcare provider for any health concerns.

Hemopatch sealing hemostat is approved for use only in selected countries. For specific information on the availability and regulatory status of Hemopatch sealing hemostat room temperature in your country, we recommend contacting your local Baxter Healthcare sales representative.

Baxter and Hemopatch are trademarks of Baxter International Inc. or its subsidiaries.

GBU-AS21-250032 (v1.0) 01/2026

Photo - https://mma.prnasia.com/media2/2859987/Hemopatch_OR.jpg?p=medium600

Photo - https://mma.prnasia.com/media2/2859988/HemopatchIRI_AU.jpg?p=medium600

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Baxter's Room Temperature HEMOPATCH Sealing Hemostat Gains Momentum in Australia and New Zealand

Baxter's Room Temperature HEMOPATCH Sealing Hemostat Gains Momentum in Australia and New Zealand

Baxter's Room Temperature HEMOPATCH Sealing Hemostat Gains Momentum in Australia and New Zealand

Baxter's Room Temperature HEMOPATCH Sealing Hemostat Gains Momentum in Australia and New Zealand

Recommended Articles